Eribulin Mesylate
FDA-approved product (solution, intravenous), marketed as Eribulin Mesylate, Halaven.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Breast cancer
- Breast carcinoma
- Breast neoplasm
- Cancer
- Liposarcoma
- Neoplasm
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other antineoplastic agents
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA46.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli41.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae39.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis53.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Eribulin Mesylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Galantamine HydrobromideExisting use: Alzheimer disease, Dementia89.6% AI-predicted activityagainst K. pneumoniaeLab records exist50+ registered studies
- Chlorhexidine GluconateExisting use: Eye infection, Gingivitis, Infection and 2 more69.3% AI-predicted activityagainst K. pneumoniaeLab records exist50+ registered studies
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives68.0% AI-predicted activityagainst K. pneumoniaeLab records exist50+ registered studies
- ElvitegravirExisting use: HIV infection, HIV-1 infection, Viral disease60.2% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Caspofungin AcetateExisting use: Aspergillosis, Candidemia, Candidiasis and 1 more57.5% AI-predicted activityagainst K. pneumoniae50+ registered studies
- DactinomycinExisting use: Kidney Wilms tumor, Neoplasm56.8% AI-predicted activityagainst K. pneumoniae50+ registered studies
- CyclosporineExisting use: Conjunctivitis, Corneal disease, Eye disease and 6 more56.1% AI-predicted activityagainst K. pneumoniae50+ registered studies
- LinaclotideExisting use: Constipation, Constipation disorder, Irritable bowel syndrome56.0% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Irinotecan HydrochlorideExisting use: Adenocarcinoma, Cancer, Carcinoma and 4 more54.5% AI-predicted activityagainst K. pneumoniae50+ registered studies
- OxytocinExisting use: Hemorrhage, Uterine Inertia52.7% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Micafungin SodiumExisting use: Candidiasis52.4% AI-predicted activityagainst K. pneumoniae50+ registered studies
- VoclosporinExisting use: Immune system disease, Lupus nephritis52.2% AI-predicted activityagainst K. pneumoniae28 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer
NCT07406542 · start 2026-04-01
Registered record
- Registry ID
- NCT07406542
- Conditions
- Recurrent or Metastatic Breast Cancer
- Interventions
- SYS6010; Investigator's Choice of Chemotherapy (eribulin, capecitabine, gemcitabine, or vinorelbine)
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Not yet recruiting
- Start
- 2026-04-01
- Completion
- 2030-04-01
- Enrolment
- 400
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRecurrent or Metastatic Breast CancerInterventionSYS6010; Investigator's Choice of Chemotherapy (eribulin, capecitabine, gemcitabine, or vinorelbine)PhasePhase 3Registry statusNot yet recruitingTesting the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer
NCT06590558 · start 2025-08-04
Registered record
- Registry ID
- NCT06590558
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Invasive Breast Carcinoma; Locally Advanced HER2-Negative Breast Carcinoma; Locally Advanced Hormone Receptor-Positive Breast Carcinoma; Locally Advanced Triple-Negative Breast Carcinoma; Metastatic HER2-Negative Breast Carcinoma; Metastatic Hormone Receptor-Positive Breast Carcinoma; Metastatic Triple-Negative Breast Carcinoma; Unresectable HER2-Negative Breast Carcinoma; Unresectable Hormone Receptor-Positive Breast Carcinoma; Unresectable Triple-Negative Breast Carcinoma
- Interventions
- Biopsy Procedure; Biospecimen Collection; Computed Tomography; Eribulin Mesylate; Magnetic Resonance Imaging; Tolinapant; X-Ray Imaging
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Withdrawn
- Start
- 2025-08-04
- Completion
- 2027-05-17
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAnatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Invasive Breast Carcinoma; Locally Advanced HER2-Negative Breast Carcinoma +8 moreInterventionBiopsy Procedure; Biospecimen Collection; Computed Tomography; Eribulin Mesylate +3 morePhasePhase 1Registry statusWithdrawnOptimal Application Timing of ADC Drugs for Advanced Breast Cancer
NCT07657130 · start 2025-07-01
Registered record
- Registry ID
- NCT07657130
- Conditions
- Breast Cancer Females
- Interventions
- Antibody drug conjugate; Chemotherapy
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2025-07-01
- Completion
- 2026-12-30
- Enrolment
- 120
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast Cancer FemalesInterventionAntibody drug conjugate; ChemotherapyPhasePhase 2Registry statusRecruitingClinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer
NCT06678230 · start 2024-11
Registered record
- Registry ID
- NCT06678230
- Conditions
- Breast Cancer
- Interventions
- Anlotinib
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Unknown
- Start
- 2024-11
- Completion
- 2025-10-20
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast CancerInterventionAnlotinibPhasePhase 2Registry statusUnknownOrganoid-based Functional Precision Therapy for Advanced Breast Cancer
NCT06102824 · start 2024-10-01
Registered record
- Registry ID
- NCT06102824
- Conditions
- HER2-negative Breast Cancer; Advanced Breast Cancer
- Interventions
- Organoid-guided treatment; Taxane; Capecitabine; Gemcitabine; Vinorelbine; Eribulin; Anthracycline; Carboplatin; Utidelone; Trastuzumab deruxtecan; Sacituzumab govitecan
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2024-10-01
- Completion
- 2028-06-30
- Enrolment
- 252
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHER2-negative Breast Cancer; Advanced Breast CancerInterventionOrganoid-guided treatment; Taxane; Capecitabine; Gemcitabine +7 morePhasePhase 2Registry statusRecruitingFDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
NCT06519370 · start 2024-08-09
Registered record
- Registry ID
- NCT06519370
- Conditions
- Triple Negative Breast Cancer
- Interventions
- FDA018-ADC; Eribulin; Capecitabine; Gemcitabine; Vinorelbine
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Active not recruiting
- Start
- 2024-08-09
- Completion
- 2027-06-20
- Enrolment
- 350
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTriple Negative Breast CancerInterventionFDA018-ADC; Eribulin; Capecitabine; Gemcitabine +1 morePhasePhase 3Registry statusActive not recruitingFluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer
NCT07371910 · start 2024-06-12
Registered record
- Registry ID
- NCT07371910
- Conditions
- Metastatic Breast Cancer; HRD-Positive/HER2-Negative Advanced Breast Cancer
- Interventions
- Chemotherapy/ADC Regimen; Fluorizoparib; Apatinib; Physician's Choice Chemotherapy/ADC Regimen
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Active not recruiting
- Start
- 2024-06-12
- Completion
- 2031-03
- Enrolment
- 200
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMetastatic Breast Cancer; HRD-Positive/HER2-Negative Advanced Breast CancerInterventionChemotherapy/ADC Regimen; Fluorizoparib; Apatinib; Physician's Choice Chemotherapy/ADC RegimenPhasePhase 3Registry statusActive not recruitingJSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
NCT06079983 · start 2023-12-01
Registered record
- Registry ID
- NCT06079983
- Conditions
- Breast Cancer
- Interventions
- JSKN003; Capecitabine tablets; Gemcitabine hydrochloride for injection; Vinorelbine tartrate injection; Paclitaxel for injection (albumin-bound type); Docetaxel injection; Eribulin mesylate injection
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Recruiting
- Start
- 2023-12-01
- Completion
- 2029-03-01
- Enrolment
- 400
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast CancerInterventionJSKN003; Capecitabine tablets; Gemcitabine hydrochloride for injection; Vinorelbine tartrate injection +3 morePhasePhase 3Registry statusRecruitingEfficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer
NCT06143553 · start 2023-09-25
Registered record
- Registry ID
- NCT06143553
- Conditions
- Metastatic Breast Cancer (MBC)
- Interventions
- Paclitaxel Polymeric Micelles for Injection; Eribulin Mesilate injection; Capecitabine Tablets; Gemcitabine Hydrochloride for Injection; Vinorelbine Tartrate Injection; Paclitaxel (albumin-bound)
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Unknown
- Start
- 2023-09-25
- Completion
- 2025-12
- Enrolment
- 168
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMetastatic Breast Cancer (MBC)InterventionPaclitaxel Polymeric Micelles for Injection; Eribulin Mesilate injection; Capecitabine Tablets; Gemcitabine Hydrochloride for Injection +2 morePhasePhase 3Registry statusUnknownSHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial
NCT05814354 · start 2023-06-30
Registered record
- Registry ID
- NCT05814354
- Conditions
- Breast Cancer
- Interventions
- SHR-A1811; Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Active not recruiting
- Start
- 2023-06-30
- Completion
- 2028-06-30
- Enrolment
- 551
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast CancerInterventionSHR-A1811; Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxelPhasePhase 3Registry statusActive not recruitingA Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
NCT05824975 · start 2023-05-30
Registered record
- Registry ID
- NCT05824975
- Conditions
- Advanced Solid Tumor; Metastatic Solid Tumor; Soft Tissue Sarcoma (STS); Platinum-resistant Ovarian Cancer (PROC); Hepatocellular Carcinoma (HCC); Colorectal Cancer (CRC); HER2 Negative Breast Cancer; Cutaneous Melanoma; Renal Cell Carcinoma (RCC)
- Interventions
- GI-102 subcutaneous (SC); GI-102; doxorubicin; paclitaxel; bevacizumab; eribulin; trastuzumab deruxtecan (T-DXd); pembrolizumab; GI-102
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Recruiting
- Start
- 2023-05-30
- Completion
- 2027-04-24
- Enrolment
- 358
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAdvanced Solid Tumor; Metastatic Solid Tumor; Soft Tissue Sarcoma (STS); Platinum-resistant Ovarian Cancer (PROC) +5 moreInterventionGI-102 subcutaneous (SC); GI-102; doxorubicin; paclitaxel +5 morePhasePhase 1 / Phase 2Registry statusRecruitingPIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin
NCT05810870 · start 2023-05-24
Registered record
- Registry ID
- NCT05810870
- Conditions
- Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer
- Interventions
- MEN1611; Eribulin
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Active not recruiting
- Start
- 2023-05-24
- Completion
- 2027-07
- Enrolment
- 14
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast Cancer; Advanced Breast Cancer; Metastatic Breast CancerInterventionMEN1611; EribulinPhasePhase 2Registry statusActive not recruitingImplantable Microdevice for TNBC - Pilot Study
NCT05774886 · start 2023-05
Registered record
- Registry ID
- NCT05774886
- Conditions
- Triple Negative Breast Cancer; Breast Cancer Stage II; Breast Cancer Stage III; Breast Cancer; Early Stage Triple-Negative Breast Carcinoma; Breast Neoplasms; Breast Carcinoma
- Interventions
- Implantable Microdevice (IMD)
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Withdrawn
- Start
- 2023-05
- Completion
- 2028-09-01
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTriple Negative Breast Cancer; Breast Cancer Stage II; Breast Cancer Stage III; Breast Cancer +3 moreInterventionImplantable Microdevice (IMD)PhasePhase 1Registry statusWithdrawnFamitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.
NCT05760378 · start 2023-03-17
Registered record
- Registry ID
- NCT05760378
- Conditions
- Triple-Negative Breast Cancer
- Interventions
- Famitinib; Camrelizumab; nab-Palitaxel/Capecitabine/Eribulin Mesylate/Carboplatin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Recruiting
- Start
- 2023-03-17
- Completion
- 2027-01-01
- Enrolment
- 223
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTriple-Negative Breast CancerInterventionFamitinib; Camrelizumab; nab-Palitaxel/Capecitabine/Eribulin Mesylate/CarboplatinPhasePhase 3Registry statusRecruitingTrastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)
NCT05063786 · start 2021-09-14
Registered record
- Registry ID
- NCT05063786
- Conditions
- Advanced Breast Cancer
- Interventions
- Trastuzumab; Alpelisib; Fulvestrant; Vinorelbine; Capecitabine; Eribulin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Active not recruiting
- Start
- 2021-09-14
- Completion
- 2026-06
- Enrolment
- 27
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAdvanced Breast CancerInterventionTrastuzumab; Alpelisib; Fulvestrant; Vinorelbine +2 morePhasePhase 3Registry statusActive not recruiting